These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 33466394)

  • 41. Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.
    Shin HG; Yang HR; Yoon A; Lee S
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting histone methylation for colorectal cancer.
    Huang T; Lin C; Zhong LL; Zhao L; Zhang G; Lu A; Wu J; Bian Z
    Therap Adv Gastroenterol; 2017 Jan; 10(1):114-131. PubMed ID: 28286564
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging Roles of lncRNAs in the Formation and Progression of Colorectal Cancer.
    He Q; Long J; Yin Y; Li Y; Lei X; Li Z; Zhu W
    Front Oncol; 2019; 9():1542. PubMed ID: 32010629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Roles of circular RNAs in colorectal cancer.
    Zhang M; Wang S
    Oncol Lett; 2021 Aug; 22(2):602. PubMed ID: 34188704
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The emerging role of long non-coding RNAs in the drug resistance of colorectal cancer.
    Chen DL; Xu RH
    Int J Clin Exp Pathol; 2018; 11(10):4735-4743. PubMed ID: 31949549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genomic diversity of colorectal cancer: Changing landscape and emerging targets.
    Ahn DH; Ciombor KK; Mikhail S; Bekaii-Saab T
    World J Gastroenterol; 2016 Jul; 22(25):5668-77. PubMed ID: 27433082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T-cell-based immunotherapy in colorectal cancer.
    Feng M; Zhao Z; Yang M; Ji J; Zhu D
    Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epigenetic Drug Therapy in the Treatment of Colorectal Cancer.
    Parizadeh SM; Jafarzadeh-Esfehani R; Ghandehari M; Seifi S; Parizadeh SMR; Moetamani-Ahmadi M; Hassanian SM; Khazaei M; Ghayour-Mobarhan M; Ferns GA; Avan A
    Curr Pharm Des; 2018; 24(23):2701-2709. PubMed ID: 30062956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Emerging Landscape of Long Non-Coding RNAs in Colorectal Cancer Metastasis.
    Liao Z; Nie H; Wang Y; Luo J; Zhou J; Ou C
    Front Oncol; 2021; 11():641343. PubMed ID: 33718238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer.
    Grifantini R; Taranta M; Gherardini L; Naldi I; Parri M; Grandi A; Giannetti A; Tombelli S; Lucarini G; Ricotti L; Campagnoli S; De Camilli E; Pelosi G; Baldini F; Menciassi A; Viale G; Pileri P; Cinti C
    J Control Release; 2018 Jun; 280():76-86. PubMed ID: 29733876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical application of genetics in management of colorectal cancer.
    Kim ER; Kim YH
    Intest Res; 2014 Jul; 12(3):184-93. PubMed ID: 25349592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular therapy of colorectal cancer: progress and future directions.
    Weng W; Feng J; Qin H; Ma Y
    Int J Cancer; 2015 Feb; 136(3):493-502. PubMed ID: 24420815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
    Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA
    Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Colorectal carcinogenesis--update and perspectives.
    Raskov H; Pommergaard HC; Burcharth J; Rosenberg J
    World J Gastroenterol; 2014 Dec; 20(48):18151-64. PubMed ID: 25561783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer.
    Shi L; Xu Y; Feng M
    Dig Dis Sci; 2023 Feb; 68(2):370-379. PubMed ID: 36575326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An update on the use of immunotherapy in patients with colorectal cancer.
    Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
    [No Abstract]   [Full Text] [Related]  

  • 57. Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer.
    Nordgaard C; Doll S; Matos ALSA; Høeberg M; Kazi JU; Friis S; Stenvang J; Rönnstrand L; Mann M; Manuel Afonso Moreira J
    Mol Oncol; 2019 Dec; 13(12):2646-2662. PubMed ID: 31545548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer.
    Kocoglu H; Velibeyoglu FM; Karaca M; Tural D
    World J Gastrointest Oncol; 2016 Jan; 8(1):1-7. PubMed ID: 26798432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.